Gynecologic Cancer

The OnPrime trial will investigate if adding Olvi-Vec, a modified virus, to chemotherapy and Avastin will improve outcomes for pretreated platinum-resistant or refractory ovarian cancer.

Maintenance therapy helps deter undetectable cancer that may exist after initial treatment.

Treatment with Libtayo may improve survival over a 30-month period with no new side effects in patients with recurrent or metastatic cervical cancer, opening the doors for an immunotherapy option for these patients.

Lenvima plus Keytruda improved survival outcomes for patients with pretreated advanced endometrial cancer, according to recent clinical trial data.

Rubraca improved progression-free survival in patients with BRCA1/2-mutant, platinum-sensitive, relapsed ovarian cancer, according to findings from the ARIEL4 clinical trial.

Cervical cancer survivor Ginny Marable heard about a story of a fellow cervical cancer survivor, Tamika Felder, not being able to preserve her fertility. The story moved Marable so much that she and her husband donated their embryos to Felder.

I am still here fighting, fighting hard and I will continue to do so to make sure I have more graduations, more weddings, and more everything that I can squeeze into my precious time left here on earth.

Adding Rivoceranib to pegylated liposomal doxorubicin — a type of chemotherapy — improved survival outcomes for patients with platinum-resistant ovarian cancer, according to recent study results.

The manufacturer of one of the cancer treatments announced that it is also participating in clinical trials assessing the safety and efficacy of their product in colorectal and endometrial cancer.

The study the FDA allowed to continue is investigating the safety and efficacy of the novel cancer drug ACR-368 in patients with endometrial, urothelial and ovarian cancer.

Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers.

The FDA approval of the first poly (adenosine diphosphate-ribose) polymerase, or PARP, inhibitor in the 2010s has drastically changed how patients with gynecologic cancers are treated.

The use of newer tools and techniques may be reducing the risk of surgical site infections and other complications in patients receiving treatment for gynecologic cancers.

I was told that I would miscarry my pregnancy, but continued to feel more pregnant, leading to my molar pregnancy diagnosis — a condition I’ve never heard of before. 

The Strata PATH trial will use a novel testing strategy to determine if certain patients with solid tumors can benefit from already-approved therapies.

Treatment with an investigational cancer vaccine plus Tecentriq was associated with positive outcomes in patients with heavily pre-treated advanced cervical cancer, according to findings from an interim analysis of a phase 2 trial.

Donna MacDonald, B.S.N., RN, OCN, CCM, goes beyond her duties as a nurse to advocate and support her patients.

The first patient was dosed in an early-phase trial evaluating the investigational cell therapy DeTIL-0255 for the treatment of advanced ovarian, cervical and endometrial cancer.

The year 2022 has already been filled with obstacles and heartache — as well plans for a new cancer treatment — but I’m putting away the bad thoughts to get ready for the fight ahead of me.

Keytruda was well tolerated and demonstrated practice-changing responses with potential for a curative approach in a group of patients with advanced endometrial cancer, according to an expert.

Today is my birthday, and while I’ve had some unforeseen changes in my cancer treatment lately, I’m grateful to still be here to celebrate.

AstraZeneca, the manufacturer of the drug, announced that treatment with Imfinzi plus chemoradiotherapy did not improve survival compared with standard-of-care chemoradiotherapy alone in patients with locally advanced cervical cancer.

There were no major differences in survival when comparing intravenous and intraperitoneal chemotherapy plus Avastin in patients with advanced ovarian cancer, research shows.

“These results position mirvetuximab soravtansine to become a practice-changing, biomarker-driven, standard-of-care treatment option for patients with (high folate receptor-alpha)-positive, platinum-resistant ovarian cancer,” noted one of the study authors.

Zejula plus Avastin led to promising progression-free survival rates with no new side effects for patients with newly diagnosed, advanced ovarian cancer.

The FDA’s approval of Keytruda is indicated for patients with advanced endometrial carcinoma with specific genetic characteristics whose disease progressed after systemic therapy and are not suitable for surgery or radiation.

The vaccine, which protects patients from seven different strains related to HPV-related cancers, may be considered part of routine oncology care for survivors.

The FDA approved Keytruda for use with chemotherapy with or without bevacizumab, for the treatment of a subset of patients with cervical cancer.

Side effects from early-onset menopause from medical treatments may be mitigated with hormone replacement therapy.

Tivdak is a targeted therapy that showed promising results for patients with pretreated metastatic or recurrent cervical cancer.